Kura肿瘤学 KURA 深 沪
已收盘 08-01 16:00:00 美东时间
6.02
-0.030
-0.50%
华盛通- 最 高6.09
- 今 开6.00
- 成交量 118.81万股
- 最 低 5.865
- 昨 收 6.05
- 总市值 5.21亿
- 52周最高 21.569
- 市盈率 静 --
- 换手率 1.37%
- 52周最低 5.41
- 委 比 -47.83%
- 总股本 8657.47万
- 历史最高 43.00
- 量 比 1.15
- 振 幅 3.72%
- 历史最低 2.50
- 每 手 1
- 风险率 4.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kura Oncology to Report Second Quarter 2025 Financial Results
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer medicines, will report its second quarter 2025 financial results on August 7, 2025, followed by a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT. Ziftomenib, its lead candidate, has received FDA Breakthrough Therapy Designation for relapsed or refractory NPM1-mutant AML and is under review with a PDUFA date of November 30, 2025. The company is also a...
07-31 11:30
SAKURA Internet Revises Earnings Forecast Amid GPU Sales Decline
An announcement from SAKURA Internet Inc. ( ($JP:3778) ) is now available. SAKU...
07-29 07:52
Kyverna Therapeutics appoints Marc Grasso as CFO
Kyverna Therapeutics (NASDAQ:KYTX) announced on Monday the appointment of Marc Grasso as its chief financial officer (CFO), effective today. Most recently, Grasso served as CFO of Alector, a clinical...
06-30 21:32
Cantor Fitzgerald Reiterates Overweight on Kura Oncologyto Overweight
Cantor Fitzgerald analyst Li Watsek reiterates Kura Oncology (NASDAQ:KURA) from Overweight to Overweight.
06-26 21:36
Kura Sushi USA to Announce Fiscal Third Quarter 2025 Financial Results on July 8, 2025
Kura Sushi USA will host a conference call on July 8, 2025, to discuss their fiscal third quarter 2025 financial results. The call, hosted by Hajime “Jimmy” Uba, Jeff Uttz, and Benjamin Porten, will begin at 5:00 p.m. ET. Interested parties can join by phone at 201-689-8471 or via webcast at www.kurasushi.com. A replay will be available shortly after the call. Kura Sushi has 77 locations across the U.S. and offers a revolving sushi service. For i...
06-24 13:00
美股大行评级 | 潜在涨幅378.93%！aTyr Pharma获富国银行升目标价至25美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1143101010774646784.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 富国银行：维持aTyr Pharma(ATYR)"超配"评级，目标价从17美元升至25美元</p> <p>• 摩根大通：维持Array Technologies(ARRY)"超配"评级，目标价从12美元升至13美元</p>
06-21 08:35
Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target
Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $36 price target.
06-20 20:53
SAKURA Internet Strengthens Alliance with Sojitz Corporation
SAKURA Internet Inc. ( ($JP:3778) ) has provided an announcement. SAKURA Intern...
06-20 13:52
Kura Oncology Announces Positive Phase 1a/1b Trial Results
Kura Oncology ( ($KURA) ) has shared an update. On June 12, 2025, Kura Oncology...
06-19 05:54
Kura Oncology And Kyowa Kirin Report Updated Clinical Data From KOMET-007, Phase 1a/1b Trial Of Ziftomenib, In Patients With Newly Diagnosed NPM1-M And KMT2A-R AML
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML –– 93% (41/44) and
06-12 19:35
